LPAR2

Receptor lizofosfatidne kiseline 2
Receptor lizofosfatidne kiseline 2
Identifikatori
Simboli	LPAR2; EDG-4; EDG4; LPA-2; LPA2
Vanjski ID	OMIM: 605110 MGI: 1858422 HomoloGene: 3465 IUPHAR: LPA2 GeneCards: LPAR2 Gene
Ontologija gena
Molekularna funkcija	• vezivanje G-protein alfa podjedinice; • aktivnost G-protein spregnutog receptora; • proteinsko vezivanje; • vezivanje PDZ domena; • veivanje LIM domena;
Celularna komponenta	• citoplazma; • ćelijska membrana; • integralno sa ćelijskom membranom; • ćelijska površina;
Biološki proces	• activacija MAPK aktivnosti; • signalni put G-protein spregnutog receptora; • aktivacija fosfolipaze C; • povišenje koncentracije citozolnih jona kalcijuma;
Pregled RNK izražavanja
	podaci
Ortolozi
Vrsta	Čovek
Entrez	9170
Ensembl	ENSG00000064547
UniProt	Q9HBW0
RefSeq (mRNA)	NM_004720.5
RefSeq (protein)	NP_004711.2
Lokacija (UCSC)	Chr 19:; 19.73 - 19.74 Mb
PubMed pretraga	[1]

Receptor lizofosfatidne kiseline 2 (LPA₂) je protein koji je kod ljudi kodiran LPAR2 genom.^[1]^[2]^[3] LPA₂ je G protein spregnuti receptor za koji se vezuje lipidni signalni molekul lizofosfatidna kiselina (LPA).^[4]

Funkcija[уреди | уреди извор]

Ovaj protein je član familije I G protein spregnutih receptora, kao i EDG familije. Ovaj protein funkcioniše kao receptor lizofosfatidne kiseline i doprinosi mobilizaciji Ca²⁺. To je kritični ćelijski respons na LPA, putem asocijacije sa Gi i Gq proteinima.^[1]

Interakcije[уреди | уреди извор]

LPAR2 formira interakcije sa TRIP6.^[5]

Reference[уреди | уреди извор]

^ ^а ^б „Entrez Gene: LPAR2 Lysophosphatidic acid receptor 2”.
^ An S, Bleu T, Hallmark OG, Goetzl EJ (1998). „Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid”. J. Biol. Chem. 273 (14): 7906—10. PMID 9525886. doi:10.1074/jbc.273.14.7906.
^ An S, Bleu T, Zheng Y, Goetzl EJ (1998). „Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization”. Mol. Pharmacol. 54 (5): 881—8. PMID 9804623.
^ Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J (2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology. 50 (1): 157—186. PMID 20055701. doi:10.1146/annurev.pharmtox.010909.105753. ^{[мртва веза]}
^ Xu, Jun; Lai Yun-Ju; Lin Weei-Chin; Lin Fang-Tsyr (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor”. J. Biol. Chem. United States. 279 (11): 10459—68. ISSN 0021-9258. PMID 14688263. doi:10.1074/jbc.M311891200.

Literatura[уреди | уреди извор]

Spiegel S (2000). „Sphingosine 1-phosphate: a ligand for the EDG-1 family of G-protein-coupled receptors.”. Ann. N. Y. Acad. Sci. 905: 54—60. PMID 10818441. doi:10.1111/j.1749-6632.2000.tb06537.x.
Contos JJ, Ishii I, Chun J (2001). „Lysophosphatidic acid receptors.”. Mol. Pharmacol. 58 (6): 1188—96. PMID 11093753.
Goetzl EJ; Dolezalova H; Kong Y; et al. (1999). „Distinctive expression and functions of the type 4 endothelial differentiation gene-encoded G protein-coupled receptor for lysophosphatidic acid in ovarian cancer.”. Cancer Res. 59 (20): 5370—5. PMID 10537322.
Contos JJ, Chun J (2000). „Genomic characterization of the lysophosphatidic acid receptor gene, lp(A2)/Edg4, and identification of a frameshift mutation in a previously characterized cDNA.”. Genomics. 64 (2): 155—69. PMID 10729222. doi:10.1006/geno.2000.6122.
Bandoh K; Aoki J; Taira A; et al. (2000). „Lysophosphatidic acid (LPA) receptors of the EDG family are differentially activated by LPA species. Structure-activity relationship of cloned LPA receptors.”. FEBS Lett. 478 (1–2): 159—65. PMID 10922489. doi:10.1016/S0014-5793(00)01827-5.
Young KW; Bootman MD; Channing DR; et al. (2001). „Lysophosphatidic acid-induced Ca2+ mobilization requires intracellular sphingosine 1-phosphate production. Potential involvement of endogenous EDG-4 receptors.”. J. Biol. Chem. 275 (49): 38532—9. PMID 10954727. doi:10.1074/jbc.M006631200.
Zheng Y, Voice JK, Kong Y, Goetzl EJ (2001). „Altered expression and functional profile of lysophosphatidic acid receptors in mitogen-activated human blood T lymphocytes.”. FASEB J. 14 (15): 2387—9. PMID 11024010. doi:10.1096/fj.00-0492fje.
Hama K; Bandoh K; Kakehi Y; et al. (2002). „Lysophosphatidic acid (LPA) receptors are activated differentially by biological fluids: possible role of LPA-binding proteins in activation of LPA receptors.”. FEBS Lett. 523 (1–3): 187—92. PMID 12123830. doi:10.1016/S0014-5793(02)02976-9.
Strausberg RL; Feingold EA; Grouse LH; et al. (2003). „Generation and initial analysis of more than 15,000 full-length human and mouse cDNA sequences.”. Proc. Natl. Acad. Sci. U.S.A. 99 (26): 16899—903. PMC 139241 . PMID 12477932. doi:10.1073/pnas.242603899.
Fujita T; Miyamoto S; Onoyama I; et al. (2003). „Expression of lysophosphatidic acid receptors and vascular endothelial growth factor mediating lysophosphatidic acid in the development of human ovarian cancer.”. Cancer Lett. 192 (2): 161—9. PMID 12668280. doi:10.1016/S0304-3835(02)00713-9.
Hu YL, Albanese C, Pestell RG, Jaffe RB (2003). „Dual mechanisms for lysophosphatidic acid stimulation of human ovarian carcinoma cells.”. J. Natl. Cancer Inst. 95 (10): 733—40. PMID 12759391. doi:10.1093/jnci/95.10.733.
Xu J, Lai YJ, Lin WC, Lin FT (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor.”. J. Biol. Chem. 279 (11): 10459—68. PMID 14688263. doi:10.1074/jbc.M311891200.
Ota T; Suzuki Y; Nishikawa T; et al. (2004). „Complete sequencing and characterization of 21,243 full-length human cDNAs.”. Nat. Genet. 36 (1): 40—5. PMID 14702039. doi:10.1038/ng1285.
Grimwood J; Gordon LA; Olsen A; et al. (2004). „The DNA sequence and biology of human chromosome 19.”. Nature. 428 (6982): 529—35. PMID 15057824. doi:10.1038/nature02399.
Oh YS; Jo NW; Choi JW; et al. (2004). „NHERF2 specifically interacts with LPA2 receptor and defines the specificity and efficiency of receptor-mediated phospholipase C-beta3 activation.”. Mol. Cell. Biol. 24 (11): 5069—79. PMC 416407 . PMID 15143197. doi:10.1128/MCB.24.11.5069-5079.2004.
Gerhard DS; Wagner L; Feingold EA; et al. (2004). „The status, quality, and expansion of the NIH full-length cDNA project: the Mammalian Gene Collection (MGC).”. Genome Res. 14 (10B): 2121—7. PMC 528928 . PMID 15489334. doi:10.1101/gr.2596504.

Vidi još[уреди | уреди извор]

Lizofosfolipidni receptor

Spoljašnje veze[уреди | уреди извор]

„Lysophospholipid Receptors: LPA₂”. IUPHAR Database of Receptors and Ion Channels. International Union of Basic and Clinical Pharmacology. Архивирано из оригинала 03. 03. 2016. г.
Lysophospholipid+receptors на US National Library of Medicine Medical Subject Headings (MeSH)

[entrez-1] а ^б „Entrez Gene: LPAR2 Lysophosphatidic acid receptor 2”.

[pmid9525886-2] An S, Bleu T, Hallmark OG, Goetzl EJ (1998). „Characterization of a novel subtype of human G protein-coupled receptor for lysophosphatidic acid”. J. Biol. Chem. 273 (14): 7906—10. PMID 9525886. doi:10.1074/jbc.273.14.7906.

[pmid9804623-3] An S, Bleu T, Zheng Y, Goetzl EJ (1998). „Recombinant human G protein-coupled lysophosphatidic acid receptors mediate intracellular calcium mobilization”. Mol. Pharmacol. 54 (5): 881—8. PMID 9804623.

[Choi_2010-4] Choi JW, Herr DR, Noguchi K, Yung YC, Lee CW, Mutoh T, Lin ME, Teo ST, Park KE, Mosley AN, Chun J (2010). „LPA Receptors: Subtypes and Biological Actions”. Annual Review of Pharmacology and Toxicology. 50 (1): 157—186. PMID 20055701. doi:10.1146/annurev.pharmtox.010909.105753. ^{[мртва веза]}

[pmid14688263-5] Xu, Jun; Lai Yun-Ju; Lin Weei-Chin; Lin Fang-Tsyr (2004). „TRIP6 enhances lysophosphatidic acid-induced cell migration by interacting with the lysophosphatidic acid 2 receptor”. J. Biol. Chem. United States. 279 (11): 10459—68. ISSN 0021-9258. PMID 14688263. doi:10.1074/jbc.M311891200.

[1]

[2]

[3]

[4]

[5]